Abstract
Rarely, a report enters the literature that becomes a clinical game-changer. This month’s issue of the Journal of Heart and Lung Transplantation contains a report with just such potential. Clinical investigators Schranz et al, in their article, ‘‘Pulmonary artery banding in infants and young children with left ventricular dilated cardiomyopathy: A novel therapeutic strategy before heart transplantation,’’ postulated that among infants aged o24 months with endstage dilated left ventriculopathy, heart failure might be controlled by the relatively simple act of ‘‘reversible’’ pulmonary artery banding (rPAB). Done with care, in properly selected candidates, rPAB appears to:
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
